Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
205 studies found for:    immune, niaid | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
Conditions: X-linked Severe Combined Immunodeficiency;   XSCID;   SCID-X1;   Gamma C-Deficient SCID
Interventions: Other: Gene-modified CD34+ Hematopoietic stem cells;   Drug: Busulfan
22 Recruiting Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Condition: Primary Immune Deficiency
Intervention:
23 Recruiting Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Condition: Chronic Granulomatous Disease
Intervention:
24 Recruiting Influenza in People With Normal and Weakened Immune Systems
Condition: Influenza
Intervention:
25 Recruiting Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults
Conditions: Prevention of Zika Infection;   Zika-Specific Immune Response
Intervention: Biological: VRC-ZKADNA085-00-VP
26 Recruiting Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses
Conditions: Healthy Volunteers;   Abnormal Phagocyte Function
Intervention:
27 Recruiting Human Immunity Against Staphylococcus Aureus Skin Infection
Condition: Staphylococcus Aureus Skin Infection
Intervention: Other: Killed Bacteria
28 Recruiting Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Condition: Ebola Virus Disease
Intervention:
29 Recruiting Detection and Characterization of Infections and Infection Susceptibility
Conditions: Immune Disorders;   Chronic Granulomatous Disease;   Genetic Immunological Deficiencies;   Hyperimmunoglobulin-E Recurrent Infection Syndrome;   Recurrent Infections;   Unknown Immune Deficiency;   GATA2 Deficiency (MonoMAC);   Nontuberculous Mycobacterial Infections;   Hyper IgE (Job s) Syndrome;   Leukocyte Adhesion Deficiency;   Susceptibility to Disseminated Infections;   Primary Immune Deficiency Disease (PIDD)
Intervention:
30 Recruiting Parasitic Infections of the Gastrointestinal Tract
Conditions: Amebiasis;   Cryptosporidiosis;   Giardiasis;   Parasitic Disease;   Parasitic Intestinal Disease;   Gastrointestinal Helminth Infections
Intervention:
31 Recruiting Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
Condition: Coccidioidomycosis
Intervention:
32 Recruiting Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide
Condition: Chronic Granulomatous Disease
Interventions: Drug: Pre-Transplant Conditioning Medications;   Other: Haploidentical Cellular Infusion;   Drug: Post-Trasnplant Medications;   Radiation: Total Body Irradiation
33 Recruiting Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
Conditions: Liver Transplant;   Liver Transplantation
Intervention: Procedure: Immunosuppression withdrawal
34 Recruiting CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)
Condition: HIV, Inflammation
Interventions: Drug: Assess Safety;   Drug: Effect of drug on viral load;   Drug: Effect of drug on T-cell count;   Drug: Effect of drug on inflammatory biomarkers
35 Recruiting Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure
Condition: Healthy Volunteers
Intervention: Drug: rVSVdeltaG-ZEBOV GP (2X 107 pfu/mL)
36 Recruiting High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
Condition: X-Linked Chronic Granulomatious Disease
Interventions: Drug: Campath;   Drug: Busulfan;   Other: allogeneic peripheral blood allograft infusion;   Drug: cyclophosphamide
37 Recruiting Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
Condition: Asthma
Intervention:
38 Recruiting A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory
Conditions: Tick-Borne Encephalitis;   Encephalitis, Tick-Borne;   Tick-Borne Disease;   Glycoprotein E, Flavivirus;   NSI Protein, Flavivirus
Intervention: Biological: FSME-IMMUN 0.5ml Baxter
39 Recruiting Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Condition: Autoimmune Lymphproliferative Syndrome
Intervention:
40 Recruiting Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Conditions: Anticytokine Autoantibody-Associated Diseases;   Disseminated Non-Tuberculous Mycobacteria;   Chronic Mucocutaneous Candidiasis;   Pulmonary Alveolar Proteinosis (PAP)
Intervention: Drug: Rituximab/Rituxan

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.